Alterity Therapeutics (ASX:ATH) Other Operating Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
34 GF Score
Price A$0.62
View Full Analysis

What is Alterity Therapeutics Other Operating Expense?

Alterity Therapeutics ASX:ATH -5.38% 34 Other Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 34/100.

Alterity Therapeutics's Other Operating Expense for the three months ended in Dec. 2025 was A$0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Alterity Therapeutics's annual Other Operating Expense declined from Jun. 2023 (A$-3.79 Mil) to Jun. 2024 (A$-3.87 Mil) and declined from Jun. 2024 (A$-3.87 Mil) to Jun. 2025 (A$-7.41 Mil).

Alterity Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Other Operating Expense Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.41 -5.07 -3.79 -3.87 -7.41

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ATH
34GF Score
Alterity Therapeutics Ltd ASX:ATH
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of A$0.00 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Other Operating Expense of A$0.00 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Other Operating Expense too high?
Alterity Therapeutics' current Other Operating Expense is A$0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Other Operating Expense compare to VRTX and REGN?
Alterity Therapeutics' Other Operating Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Other Operating Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Other Operating Expense of A$0.00 Mil. The current Other Operating Expense is A$0.00 Mil. Alterity Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Other Operating Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
34GF Score

Get the complete analysis for ASX:ATH

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.62
Price